Perspectives in Peptide-Based Vaccination Strategies for Syndrome Coronavirus 2 Pandemic

Natale, Concetta Di; Manna, Sara La; Benedictis, Ilaria De; Brandi, Paola; Marasco, Daniela

doi:10.3389/fphar.2020.578382

Cited by 44 publications

(36 citation statements)

References 166 publications

(264 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peptide vaccines are considered as the most significant therapeutic compounds for viral infections ( Agarwal and Gabrani, 2020 ; Brice and Diamond, 2020 ; Kalita et al, 2020 ). Further, novel delivery modes facilitate peptides as prominent vaccine candidates for COVID-19 ( Di Natale et al, 2020 ).…”

Section: Present Status and Future Perspectivesmentioning

confidence: 99%

Emerging Therapeutic Approaches to Combat COVID-19: Present Status and Future Perspectives

Vivekanandhan¹,

Poornima²,

Barabadi

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

Coronavirus disease (COVID-19) has emerged as a fast-paced epidemic in late 2019 which is disrupting life-saving immunization services. SARS-CoV-2 is a highly transmissible virus and an infectious disease that has caused fear among people across the world. The worldwide emergence and rapid expansion of SARS-CoV-2 emphasizes the need for exploring innovative therapeutic approaches to combat SARS-CoV-2. The efficacy of some antiviral drugs such as remdesivir, favipiravir, umifenovir, etc., are still tested against SARS-CoV-2. Additionally, there is a large global effort to develop vaccines for the protection against COVID-19. Because vaccines seem the best solution to control the pandemic but time is required for its development, pre-clinical/clinical trials, approval from FDA and scale-up. The nano-based approach is another promising approach to combat COVID-19 owing to unique physicochemical properties of nanomaterials. Peptide based vaccines emerged as promising vaccine candidates for SARS-CoV-2. The study emphasizes the current therapeutic approaches against SARS-CoV-2 and some of the potential candidates for SARS-CoV-2 treatment which are still under clinical studies for their effectiveness against SARS-CoV-2. Overall, it is of high importance to mention that clinical trials are necessary for confirming promising drug candidates and effective vaccines and the safety profile of the new components must be evaluated before translation of in vitro studies for implementation in clinical use.

show abstract

Section: Present Status and Future Perspectivesmentioning

confidence: 99%

Emerging Therapeutic Approaches to Combat COVID-19: Present Status and Future Perspectives

Vivekanandhan¹,

Poornima²,

Barabadi

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…The third example is the development of the IMP-CoVac-1 vaccine by IMV Inc., which has entered a phase 1 clinical trial. 113 This vaccine is based on the use of a lipid-based DPX platform that can be formulated with peptide antigens, which are capable of activating B- and T-cell responses. The vaccine can be stored for extended time periods in a dry form and is easy to reconstitute for injection.…”

Section: Nano-enabled Protein Subunit/peptide Vaccines and Virus-likementioning

confidence: 99%

Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape

Nel

Miller

2021

ACS Nano

View full text Add to dashboard Cite

At the time of preparing this Perspective, large-scale vaccination for COVID-19 is in progress, aiming to bring the pandemic under control through vaccine-induced herd immunity. Not only does this vaccination effort represent an unprecedented scientific and technological breakthrough, moving us from the rapid analysis of viral genomes to design, manufacture, clinical trial testing, and use authorization within the time frame of less than a year, but it also highlights rapid progress in the implementation of nanotechnology to assist vaccine development. These advances enable us to deliver nucleic acid and conformation-stabilized subunit vaccines to regional lymph nodes, with the ability to trigger effective humoral and cellular immunity that prevents viral infection or controls disease severity. In addition to a brief description of the design features of unique cationic lipid and virus-mimicking nanoparticles for accomplishing spike protein delivery and presentation by the cognate immune system, we also discuss the importance of adjuvancy and design features to promote cooperative B- and T-cell interactions in lymph node germinal centers, including the use of epitope-based vaccines. Although current vaccine efforts have demonstrated short-term efficacy and vaccine safety, key issues are now vaccine durability and adaptability against viral variants. We present a forward-looking perspective of how vaccine design can be adapted to improve durability of the immune response and vaccine adaptation to overcome immune escape by viral variants. Finally, we consider the impact of nano-enabled approaches in the development of COVID-19 vaccines for improved vaccine design against other infectious agents, including pathogens that may lead to future pandemics.

show abstract

“…85 Currently, many peptide-based SARS-CoV-2 vaccine candidates are being used in clinical trials. 86…”

Section: Subunit Vaccinesmentioning

confidence: 99%

Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination

et al. 2021

View full text Add to dashboard Cite

Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease (COVID-19) caused by the novel coronavirus SARS-coronavirus 2 (CoV-2). To combat the devastating spread of SARS-CoV-2, extraordinary efforts from numerous laboratories have focused on the development of effective and safe vaccines. Traditional live-attenuated or inactivated viral vaccines are not recommended for immunocompromised patients as the attenuated virus can still cause disease via phenotypic or genotypic reversion. Subunit vaccines require repeated dosing and adjuvant use to be effective, and DNA vaccines exhibit lower immune responses. mRNA vaccines can be highly unstable under physiological conditions. On the contrary, naturally antigenic viral vectors with well-characterized structure and safety profile serve as among the most effective gene carriers to provoke immune response via heterologous gene transfer. Viral vector-based vaccines induce both an effective cellular immune response and a humoral immune response owing to their natural adjuvant properties via transduction of immune cells. Consequently, viral vectored vaccines carrying the SARS-CoV-2 spike protein have recently been generated and successfully used to activate cytotoxic T cells and develop a neutralizing antibody response. Recent progress in SARS-CoV-2 vaccines, with an emphasis on gene therapy viral vector-based vaccine development, is discussed in this review.

show abstract

Perspectives in Peptide-Based Vaccination Strategies for Syndrome Coronavirus 2 Pandemic

Cited by 44 publications

References 166 publications

Emerging Therapeutic Approaches to Combat COVID-19: Present Status and Future Perspectives

Emerging Therapeutic Approaches to Combat COVID-19: Present Status and Future Perspectives

Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape

Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination

Contact Info

Product

Resources

About